Free Trial

Covalon Technologies (CVE:COV) Shares Down 13.4% - Time to Sell?

Covalon Technologies logo with Medical background

Covalon Technologies Ltd. (CVE:COV - Get Free Report) shares traded down 13.4% during mid-day trading on Tuesday . The company traded as low as C$2.80 and last traded at C$3.11. 160,296 shares changed hands during trading, an increase of 172% from the average session volume of 58,853 shares. The stock had previously closed at C$3.59.

Covalon Technologies Stock Down 8.4 %

The business's fifty day moving average price is C$3.54 and its 200 day moving average price is C$3.03. The firm has a market capitalization of C$90.15 million, a price-to-earnings ratio of -82.25 and a beta of 0.64. The company has a current ratio of 5.24, a quick ratio of 6.45 and a debt-to-equity ratio of 4.98.

Covalon Technologies Company Profile

(Get Free Report)

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.

Featured Articles

Should You Invest $1,000 in Covalon Technologies Right Now?

Before you consider Covalon Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Covalon Technologies wasn't on the list.

While Covalon Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines